ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2013
Prostate cancer cell phenotypes based on AGR2 and CD10 expression.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Prevalence and Significance of AGR2 Expression in Human Cancer.Cancer medicine · 2024Article
- Prostate cancer research: tools, cell types, and molecular targets.Frontiers in oncology · 2024Review
- A comprehensive review of the literature on CD10: its function, clinical application, and prospects.Frontiers in pharmacology · 2024Review
- Integrative multi-omics and drug-response characterization of patient-derived prostate cancer primary cells.Signal transduction and targeted therapy · 2023Article
- The opposing action of stromal cell proenkephalin and stem cell transcription factors in prostate cancer differentiation.BMC cancer · 2021Article
- microRNA-211-mediated targeting of the INHBA-TGF-β axis suppresses prostate tumor formation and growth.Cancer gene therapy · 2021Article
- A New CD10 Antibody Inhibits the Growth of Malignant Mesothelioma.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2021Article
- Article
- Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.JCI insight · 2019Article
- AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting.Oncotarget · 2019Article
- Article
- Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer.Oncotarget · 2018Article
- Cancer-secreted AGR2 induces programmed cell death in normal cells.Oncotarget · 2016Article
- Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2.Oncotarget · 2016Article
- In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies.Theranostics · 2016Article
- A proteomic profiling of laser-microdissected lung adenocarcinoma cells of early lepidic-types.Clinical and translational medicine · 2015Article
- Article
- Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.Oncotarget · 2015Article
- Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.Annals of surgical oncology · 2015Article
- Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition.Laboratory investigation; a journal of technical methods and pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
Abstract
The combination of expression patterns of AGR2 (anterior gradient 2) and CD10 by prostate cancer provided four phenotypes that correlated with clinical outcome. Based on immunophenotyping, CD10(low)AGR2(high), CD10(high)AGR2(high), CD10(low)AGR2(low), and CD10(high)AGR2(low) were distinguished. AGR2(+) tumors were associated with longer recurrence-free survival and CD10(+) tumors with shorter recurrence-free survival. In high-stage cases, the CD10(low)AGR2(high) phenotype was associated with a ninefold higher recurrence-free survival than the CD10(high)AGR2(low) phenotype. The CD10(high)AGR2(high) and CD10(low)AGR2(low) phenotypes were intermediate. The CD10(high)AGR2(low) phenotype was most frequent in high-grade primary tumors. Conversely, bone and other soft tissue metastases, and derivative xenografts, expressed more AGR2 and less CD10. AGR2 protein was readily detected in tumor metastases. The CD10(high)AGR2(low) phenotype in primary tumors is predictive of poor outcome; however, the CD10(low)AGR2(high) phenotype is more common in metastases. It appears that AGR2 has a protective function in primary tumors but may have a role in the distal spread of tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.